Literature DB >> 25922146

Benefit of primary tumor resection in stage IV colorectal cancer with unresectable metastasis: a multicenter retrospective study using a propensity score analysis.

Soichiro Ishihara1, Takeshi Nishikawa, Toshiaki Tanaka, Junichiro Tanaka, Tomomichi Kiyomatsu, Kazushige Kawai, Keisuke Hata, Hioaki Nozawa, Shinsuke Kazama, Hironori Yamaguchi, Eiji Sunami, Joji Kitayama, Kenichi Sugihara, Toshiaki Watanabe.   

Abstract

PURPOSE: Retrospective studies have shown that primary tumor resection improves the prognosis of patients with colorectal cancer (CRC) with unresectable metastasis (mCRC). The aim of this study was to investigate the prognostic impact of primary tumor resection in various subgroups of mCRC patients.
METHODS: A total of 1982 patients with mCRC from January 1997 to December 2007 were retrospectively evaluated. The impact of primary tumor resection on cancer-specific survival (CSS) was analyzed using propensity score analysis to mitigate selection bias. Covariates in the models for propensity scores included treatment period, age, gender, tumor location, depth, lymph node metastasis, number of metastatic organs, and carcinoembryonic antigen (CEA) levels.
RESULTS: Among the whole patient population, primary tumor resection significantly improved CSS [hazard ratio (HR) 0.46, 95% confidence interval (CI) 0.32-0.66, p < 0.01]. However, primary tumor resection did not significantly improve CSS in the following subgroups: patients treated in the first 5 years of the study (HR 0.56, 95% CI 0.28-1.13, p = 0.08), patients aged >65 years (HR 0.72, 95% CI 0.36-1.42, p = 0.31), female patients (HR 0.60, 95% CI 0.31-1.17, p = 0.13), patients with right-sided colon cancer (HR 0.68, 95% CI 0.39-1.20, p = 0.17), and patients without nodal involvement (HR 0.54, 95% CI 0.25-1.17, p = 0.09).
CONCLUSIONS: Our study suggests that primary tumor resection improves the survival of patients with mCRC. However, the prognostic benefit is different among patient subpopulations.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25922146     DOI: 10.1007/s00384-015-2228-4

Source DB:  PubMed          Journal:  Int J Colorectal Dis        ISSN: 0179-1958            Impact factor:   2.571


  28 in total

1.  Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer.

Authors:  Toshiaki Watanabe; Michio Itabashi; Yasuhiro Shimada; Shinji Tanaka; Yoshinori Ito; Yoichi Ajioka; Tetsuya Hamaguchi; Ichinosuke Hyodo; Masahiro Igarashi; Hideyuki Ishida; Megumi Ishiguro; Yukihide Kanemitsu; Norihiro Kokudo; Kei Muro; Atsushi Ochiai; Masahiko Oguchi; Yasuo Ohkura; Yutaka Saito; Yoshiharu Sakai; Hideki Ueno; Takayuki Yoshino; Takahiro Fujimori; Nobuo Koinuma; Takayuki Morita; Genichi Nishimura; Yuh Sakata; Keiichi Takahashi; Hiroya Takiuchi; Osamu Tsuruta; Toshiharu Yamaguchi; Masahiro Yoshida; Naohiko Yamaguchi; Kenjiro Kotake; Kenichi Sugihara
Journal:  Int J Clin Oncol       Date:  2011-10-15       Impact factor: 3.402

2.  Prognostic impact of primary tumor resection and lymph node dissection in stage IV colorectal cancer with unresectable metastasis: a propensity score analysis in a multicenter retrospective study.

Authors:  Soichiro Ishihara; Tamuro Hayama; Hideki Yamada; Keijiro Nozawa; Keiji Matsuda; Hiroaki Miyata; Satomi Yoneyama; Toshiaki Tanaka; Junichiro Tanaka; Tomomichi Kiyomatsu; Kazushige Kawai; Hioaki Nozawa; Takamitsu Kanazawa; Shinsuke Kazama; Hironori Yamaguchi; Eiji Sunami; Joji Kitayama; Yojiro Hashiguchi; Kenichi Sugihara; Toshiaki Watanabe
Journal:  Ann Surg Oncol       Date:  2014-04-24       Impact factor: 5.344

3.  The outcome after stent placement or surgery as the initial treatment for obstructive primary tumor in patients with stage IV colon cancer.

Authors:  Won-Suk Lee; Jeong-Heum Baek; Jin Mo Kang; Sangtae Choi; Kwang An Kwon
Journal:  Am J Surg       Date:  2012-01-20       Impact factor: 2.565

4.  Tumor location is a prognostic factor in poorly differentiated adenocarcinoma, mucinous adenocarcinoma, and signet-ring cell carcinoma of the colon.

Authors:  Soichiro Ishihara; Toshiaki Watanabe; Takuya Akahane; Ryu Shimada; Atsushi Horiuchi; Hajime Shibuya; Tamuro Hayama; Hideki Yamada; Keijiro Nozawa; Keiji Matsuda; Koutarou Maeda; Kenichi Sugihara
Journal:  Int J Colorectal Dis       Date:  2011-11-04       Impact factor: 2.571

5.  Apoptotic effects of over-expressed estrogen receptor-beta on LoVo colon cancer cell is mediated by p53 signalings in a ligand-dependent manner.

Authors:  Hsi-Hsien Hsu; Sue-Fei Cheng; Cheng-Chung Wu; Chun-Hsien Chu; Yi-Jiun Weng; Chung-Sheng Lin; Shin-Da Lee; Hung-Chien Wu; Chih-Yang Huang; Wei-Wen Kuo
Journal:  Chin J Physiol       Date:  2006-04-30       Impact factor: 1.764

6.  Outcome and natural history of patients with stage IV colorectal cancer receiving chemotherapy without primary tumor resection.

Authors:  James R Nitzkorski; Jeffrey M Farma; James C Watson; Veeraiah Siripurapu; Fang Zhu; Ronald S Matteotti; Elin R Sigurdson
Journal:  Ann Surg Oncol       Date:  2011-08-23       Impact factor: 5.344

7.  Increasing prevalence of comorbidity in patients with colorectal cancer in the South of the Netherlands 1995-2010.

Authors:  N J van Leersum; M L G Janssen-Heijnen; M W J M Wouters; H J T Rutten; J W Coebergh; R A E M Tollenaar; V E P P Lemmens
Journal:  Int J Cancer       Date:  2012-11-05       Impact factor: 7.396

8.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors:  Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

9.  Postmenopausal levels of endogenous sex hormones and risk of colorectal cancer.

Authors:  Tess V Clendenen; Karen L Koenig; Roy E Shore; Mortimer Levitz; Alan A Arslan; Anne Zeleniuch-Jacquotte
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-01       Impact factor: 4.254

10.  The performance of different propensity score methods for estimating marginal hazard ratios.

Authors:  Peter C Austin
Journal:  Stat Med       Date:  2012-12-12       Impact factor: 2.373

View more
  10 in total

1.  Management of asymptomatic primary tumours in stage IV colorectal cancer: Review of outcomes.

Authors:  Kate Jessica Wilkinson; Wei Chua; Weng Ng; Aflah Roohullah
Journal:  World J Gastrointest Oncol       Date:  2015-12-15

2.  Primary Tumor Resection in Patients with Incurable Localized or Metastatic Colorectal Cancer: A Systematic Review and Meta-analysis.

Authors:  Constantinos Simillis; Eliana Kalakouti; Thalia Afxentiou; Christos Kontovounisios; Jason J Smith; David Cunningham; Michel Adamina; Paris P Tekkis
Journal:  World J Surg       Date:  2019-07       Impact factor: 3.352

3.  Prognostic impact of lymph node dissection is different for male and female colon cancer patients: a propensity score analysis in a multicenter retrospective study.

Authors:  Soichiro Ishihara; Kensuke Otani; Koji Yasuda; Takeshi Nishikawa; Toshiaki Tanaka; Junichiro Tanaka; Tomomichi Kiyomatsu; Kazushige Kawai; Keisuke Hata; Hioaki Nozawa; Shinsuke Kazama; Hironori Yamaguchi; Eiji Sunami; Joji Kitayama; Kenichi Sugihara; Toshiaki Watanabe
Journal:  Int J Colorectal Dis       Date:  2016-03-29       Impact factor: 2.571

4.  Asymptomatic primary tumour in incurable metastatic colorectal cancer: is there a role for surgical resection prior to systematic therapy or not?

Authors:  Narimantas E Samalavicius; Audrius Dulskas; Edita Baltruskeviciene; Giedre Smailyte; Marija Skuciene; Rasa Mikelenaite; Rasa Venslovaite; Eduardas Aleknavicius; Almantas Samalavicius; Raimundas Lunevicius
Journal:  Wideochir Inne Tech Maloinwazyjne       Date:  2016-12-31       Impact factor: 1.195

5.  A phase II study of 5-fluorouracil/L-leucovorin/oxaliplatin (mFOLFOX6) in Japanese patients with metastatic or unresectable small bowel adenocarcinoma.

Authors:  Takahiro Horimatsu; Norisuke Nakayama; Toshikazu Moriwaki; Yoshinori Hirashima; Mikio Fujita; Masako Asayama; Ichiro Moriyama; Koji Nakashima; Eishi Baba; Hiroshi Kitamura; Takao Tamura; Ayumu Hosokawa; Kenichi Yoshimura; Manabu Muto
Journal:  Int J Clin Oncol       Date:  2017-05-23       Impact factor: 3.402

6.  Resection of asymptomatic primary tumour in unresectable stage IV colorectal cancer: time to move on from propensity matched scores to randomized controlled trials.

Authors:  Kjetil Søreide
Journal:  Int J Cancer       Date:  2016-07-12       Impact factor: 7.396

7.  Bevacizumab improves survival in metastatic colorectal cancer patients with primary tumor resection: A meta-analysis.

Authors:  Dedong Cao; Yongfa Zheng; Huilin Xu; Wei Ge; Ximing Xu
Journal:  Sci Rep       Date:  2019-12-30       Impact factor: 4.379

8.  Not All Kirsten Rat Sarcoma Viral Oncogene Homolog Mutations Predict Poor Survival in Patients With Unresectable Colorectal Liver Metastasis.

Authors:  Zhizun Lin; Yi Liu; Shaoxin Cai; Changshun Yang; Liyuan Zhou; Weihua Li
Journal:  Technol Cancer Res Treat       Date:  2021 Jan-Dec

9.  Efficacy of Primary Tumor Resection in Metastatic Colorectal Cancer.

Authors:  Yong Huang; Kuanxue Ge; Guangshun Fu; Junfeng Chu; Wei Wei
Journal:  Med Sci Monit       Date:  2020-08-29

10.  Efficacy of surgery and chemotherapy for stage IV small bowel adenocarcinoma: A population-based analysis using Surveillance, Epidemiology, and End Result Program database.

Authors:  Tongtong Liu; Yunlong Wu; Tao Jiang
Journal:  Cancer Med       Date:  2020-08-04       Impact factor: 4.452

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.